UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2016
Commission File Number: 001-13742
ISRAEL CHEMICALS LTD.
(Exact name of registrant as specified in its charter)
Israel Chemicals Ltd.
Millennium Tower
23 Aranha Street
P.O. Box 20245
Tel Aviv, 61202 Israel
(972-3) 684-4400
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
Form 20-F |
X |
|
Form 40-F |
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
Yes |
|
|
No |
X |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
Yes |
|
|
No |
X |
|
|
ISRAEL CHEMICALS LTD.
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number: 333-205518) of Israel Chemicals Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
|
|
|
|
1. |
Motion for disclosure and review of documents regarding the Harmonization Project |
|
|
Motion for disclosure and review of documents regarding the Harmonization Project
The Company hereby reports, that today it received a motion for disclosure and review of documents, in accordance with Section 198A of the Companies Law, 5759-1999. The motion was filed to the district court in Tel Aviv by a shareholder of the Company, as a preliminary proceeding towards the application of a certification of a derivative action with regard to the way of management and discontinuation of the Harmonization Project, which he claims allegedly led to the write-off of the amount invested in the project.
The Company, with its legal advisors, will examine the motion and shall submit its response to the court.
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
Israel Chemicals Ltd. |
|||
|
|
|
|
|||
|
|
|
|
By: |
/s/ Kobi Altman |
|
|
|
|
|
|
Name: |
Kobi Altman |
|
|
|
|
|
Title: |
Chief Financial Officer |
|
|
|
Israel Chemicals Ltd. |
|||
|
|
|
|
|||
|
|
|
|
By: |
/s/ Lisa Haimovitz |
|
|
|
|
|
|
Name: |
Lisa Haimovitz |
|
|
|
|
|
Title: |
Senior Vice President, Global General Counsel and Corporate Secretary |
Date: December 8, 2016
|
|